The impact of diabetes mellitus on healthcare costs in Italy

References

• Bustacchini S, Corsonello A, Onder G et al. Pharmacoeconomics and aging. Drugs Aging26(Suppl. 1), 75–87 (2009).
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature414(6865), 782–787 (2001).
   PubMed Web of Science ®Google Scholar
• Zimmet P. The burden of Type 2 diabetes: are we doing enough? Diabetes Metab.29(4 Pt 2), 6S9–6S18 (2003).
   PubMed Web of Science ®Google Scholar
• Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: IFD Diabetes Atlas 2009 (4th Edition). Unwin N, Whiting D, Gan D, Jacqmain O, Ghyoot G (Eds). International Diabetes Federation, Brussels, Belgium (2009).
   Google Scholar
• Brito-Sanfiel M, Diago-Cabezudo J, Calderon A. Economic impact of hypoglycemia on healthcare in Spain. Expert Rev. Pharmacoecon. Outcomes Res.10(6), 649–660 (2010).
   PubMed Web of Science ®Google Scholar
• WHO Study Group. Prevention of diabetes mellitus. Report of a WHO Study Group. WHO Tech. Rep. Ser.844, 1–100 (1994).
   PubMed Web of Science ®Google Scholar
• Zimmet PZ. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia42(5), 499–518 (1999).
   PubMed Web of Science ®Google Scholar
• Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med.14(Suppl. 5), S1–S85 (1997).
   PubMed Web of Science ®Google Scholar
• The social and cost implications of Type II diabetes. A seminar-in-print. Pharmacoeconomics8(Suppl. 1), 1–94 (1995).
   Google Scholar
• Ray N, Willis S, Thamer M. Direct and indirect cost of diabetes in the United States in 1992. American Diabetes Association, VA, USA (1993).
   Google Scholar
• Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care21(4), 518–524 (1998).
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Directory Triennial Report (1991–1994). International Diabetes Federation, Brussels, Belgium (1994).
   Google Scholar
• McCarty D, Zimmet P. Diabetes 1994 to 2010: Global Estimates and Projections. International Diabetes Institute, Melbourne, Australia (1994).
   Google Scholar
• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care21(9), 1414–1431 (1998).
   PubMed Web of Science ®Google Scholar
• IFD Diabetes Atlas (3rd Edition). International Diabetes Federation, Brussels, Belgium (2006).
   Google Scholar
• IFD Diabetes Atlas 2009 (4th Edition). Unwin N, Whiting D, Gan D, Jacqmain O, Ghyoot G (Eds). International Diabetes Federation, Brussels, Belgium (2009).
   Google Scholar
• Garancini MP. [Epidemiology of Diabetes Non-Insulin-Dependent and Impaired Glucose Tolerance]. Gruppo di studio Epidemiologia e Statistica. Il diabete in Italia (Eds). Editrice Kurtis, Milan, Italy (1996).
   Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Marchesini G, Forlani G, Rossi E, Berti A, De Rosa M; ARNO Working Group. The direct economic cost of pharmacologically-treated diabetes in Italy-2006. The ARNO observatory. Nutr. Metab. Cardiovasc. Dis.21(5), 339–346 (2011).
   PubMedGoogle Scholar
• Jonsson B; CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia45(7), S5–S12 (2002).
   PubMed Web of Science ®Google Scholar
• Massi-Benedetti M; CODE-2 Advisory Board. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia45(7), S1–S4 (2002).
   PubMed Web of Science ®Google Scholar
• Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care26(3), 917–932 (2003).
   PubMed Web of Science ®Google Scholar
• Laditka SB, Mastanduno MP, Laditka JN. Health care use of individuals with diabetes in an employer-based insurance population. Arch. Intern. Med.161(10), 1301–1308 (2001).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care31(3), 596–615 (2008).
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ. Direct medical costs of complications resulting from Type 2 diabetes in the U.S. Diabetes Care21(7), 1122–1128 (1998).
   PubMed Web of Science ®Google Scholar
• Ettaro L, Songer TJ, Zhang P, Engelgau MM. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics22(3), 149–164 (2004).
   PubMed Web of Science ®Google Scholar
• Saha S, Gerdtham UG, Johansson P. Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases. Int. J. Environ. Res. Public Health7(8), 3150–3195 (2010).
   PubMed Web of Science ®Google Scholar
• Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost–effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care33(8), 1872–1894 (2010).
   PubMed Web of Science ®Google Scholar
• Weber C, Schneider B, Lodwig V, Holm MV, Neeser K. Cost impact of blood glucose self-monitoring on complications of Type 2 diabetes: a Swiss perspective (ROSSO study No.11). Swiss Med. Wkly137(39–40), 545–550 (2007).
   PubMedGoogle Scholar
• Neeser K, Weber C. Cost impact of self-measurement of blood glucose on complications of Type 2 diabetes: the Spanish perspective. Diabetes Technol. Ther.11(8), 509–516 (2009).
   PubMedGoogle Scholar
• Tunis SL, Willis WD, Foos V. Self-monitoring of blood glucose (SMBG) in patients with Type 2 diabetes on oral anti-diabetes drugs: cost–effectiveness in France, Germany, Italy, and Spain. Curr. Med. Res. Opin.26(1), 163–175 (2010).
   PubMed Web of Science ®Google Scholar
• Tunis SL, Minshall ME. Self-monitoring of blood glucose (SMBG) for Type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US. Curr. Med. Res. Opin.26(1), 151–162 (2010).
   PubMed Web of Science ®Google Scholar
• Pollock RF, Valentine WJ, Goodall G, Brandle M. Evaluating the cost-effectiveness of self-monitoring of blood glucose in Type 2 diabetes patients on oral anti-diabetic agents. Swiss Med. Wkly40, w13103 (2010).
   Google Scholar
• Weber C, Kocher S, Neeser K, Bartaskova D. Impact of self-measurement of blood glucose on complications of Type 2 diabetes: economic analysis from a Czech perspective. Curr. Med. Res. Opin.26(2), 289–296 (2010).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339(4), 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Williams R, Van Gaal L, Lucioni C; CODE-2 Advisory Board. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia45(7), S13–S17 (2002).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care21(2), 296–309 (1998).
   PubMed Web of Science ®Google Scholar
• Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in Type 2 diabetes mellitus. Arch. Intern. Med.159(16), 1873–1880 (1999).
   PubMed Web of Science ®Google Scholar
• Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J. Clin. Endocrinol. Metab.78(4), 809A–809F (1994).
   PubMed Web of Science ®Google Scholar
• Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G; CODE-2 Italian Advisory Board. The costs of Type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat. Endocrinol.2(2), 121–133 (2003).
   PubMedGoogle Scholar
• Morsanutto A, Berto P, Lopatriello S et al. Major complications have an impact on total annual medical cost of diabetes: results of a database analysis. J. Diabetes Complications20(3), 163–169 (2006).
   PubMed Web of Science ®Google Scholar
• Ray JA, Valentine WJ, Secnik K et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr. Med. Res. Opin.21(10), 1617–1629 (2005).
   PubMed Web of Science ®Google Scholar
• Bruno G, Karaghiosoff L, Merletti F et al. The impact of diabetes on prescription drug costs: the population-based Turin study. Diabetologia51(5), 795–801 (2008).
   PubMed Web of Science ®Google Scholar
• Gregori D, Pagano E, Rosato R, Bo S, Zigon G, Merletti F. Evaluating hospital costs in type 2 diabetes care: does the choice of the model matter? Curr. Med. Res. Opin.22(10), 1965–1971 (2006).
   PubMed Web of Science ®Google Scholar
• Pagano E, Bo S, Petrinco M, Rosato R, Merletti F, Gregori D. Factors affecting hospitalization costs in Type 2 diabetic patients. J. Diabetes Complications23(1), 1–6 (2009).
   PubMed Web of Science ®Google Scholar
• Giorda C, Petrelli A, Gnavi R; Regional Board for Diabetes Care of Piemonte. The impact of second-level specialized care on hospitalization in persons with diabetes: a multilevel population-based study. Diabet. Med.23(4), 377–383 (2006).
   PubMedGoogle Scholar
• Novo G, Scordato F, Cerruto G et al. In-hospital stay of patient with acute coronary syndrome with or without diabetes mellitus. Minerva Cardioangiol.57(2), 159–164 (2009).
   PubMedGoogle Scholar
• Magoni M, Scarcella C, Vassallo F et al. The evolving burden of HIV infection compared with other chronic diseases in northern Italy. HIV Med.12(3), 129–137 (2011).
   PubMedGoogle Scholar
• Simanis JG. Health care expenditures: international comparisons, 1970–1980. Soc. Secur. Bull.50(10), 19–24 (1987).
   PubMedGoogle Scholar
• Giannini C, Mohn A, Chiarelli F. Technology and the issue of cost/benefit in diabetes. Diabetes Metab. Res. Rev.25(Suppl. 1), S34–S44 (2009).
   PubMedGoogle Scholar
• Balducci S, Zanuso S, Massarini M et al. The Italian Diabetes and Exercise Study (IDES): design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in people with Type 2 diabetes and the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis.18(9), 585–595 (2008).
   PubMed Web of Science ®Google Scholar
• Balducci S, Zanuso S, Nicolucci A et al. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with Type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch. Intern. Med.170(20), 1794–1803 (2010).
   PubMed Web of Science ®Google Scholar
• Wille E, Scholze J, Alegria E et al. Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur. J. Health Econ.12(3), 205–218 (2011).
   PubMedGoogle Scholar
• Scholze J, Alegria E, Ferri C et al. Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health10, 529 (2010).
   PubMedGoogle Scholar